



ALEMBIC PHARMA

Pharmaceuticals

07 May 2025

FY26 to be better than FY25

- Revenue/EBITDA/ PAT grew 6.7%/8% and 19% above our estimates.
 EBITDA margin reported 20bps above estimates of 15.4% in 4QFY25
- Healthy growth across segments and cost rationalisation to result in EBITDA margin clawing back to 18% by FY27
- We raise EPS by 8.9% and 7.3% by FY26E and FY27E to Rs 37.1 and Rs 48.6 per shar. Maintain BUY, ascribe PE of 21x on FY27E

Results above expectations: ALPM sales grew by 16.7%, EBITDA grew by 4.6% while PAT declined by 12%. Although sales were higher, change in the product mix led to 498bps decline in gross margin to 70% and subsequently, EBITDA margin reported at 15.4% in 4QFY25. In FY25, sales grew by 7%, EBITDA grew by 8% and PAT declined by 8% due to 40% rise in finance costs on account of rise in short-term debt and higher tax rate of 18% in FY25 due to higher provisions vs 2.5% in FY24.

Domestic sales to grow in double digits - ALPM's domestic sales grew by 8%, driven by growth in key specialty therapies (52% of domestic sales) like Gynecology, Anti-diabetic, Ophthalmology, Dermatology, acute driven therapies (30% of domestic sales) like Anti-infective and Cough & Cold and 20% growth in Animal Health (18% of domestic sales). Anti-infective therapy base has normalised, Animal Health is expected to sustain its growth momentum and due to unseasonal climate changes, we expect the domestic region to grow by 10% CAGR from FY25-27E.

New product launches to drive US sales – ALPM's US sales grew by 20% in 4QFY25 and 13% in FY25. The growth was largely led by volume growth and new product launches (4 products launched in 4Q). In FY25, ALPM filed 8 ANDAs out of which 5 were filed in 4QFY25. The company intends to launch 15 new products in FY26, out of which 20-30% is expected to be meaningful products. ALPM is increasing its R&D spend in FY26E to Rs 6bn (Rs 5.2bn in FY25), amongst that, 40% would be towards peptides, complex injectables and Ophthalmic while the rest towards APIs and OSDs. Amongst new filings, 45% would be injectables and the rest would be OSD, Derma and Ophthalmic. Due to new launches, we expect US sales to grow by 13% CAGR from FY25-27E.

ROW markets growth to be driven by deeper penetration – ALPM's ROW market grew by 43% in 4QFY25 and 18% in FY25, largely driven by sales expanded in Chile. It also has key partnership active in Europe, Canada, Australia, Brazil, and South Africa. Growth momentum is expected to sustain with new product launches and geographical diversification, hence, we expect these sales to grow at a CAGR of 15% from FY25-27E.

research@bobcaps.in

Foram Parekh

Key changes

	Target	Rating		
	<►	<►		
Ticke	er/Price	ALPM IN/Rs 887		
Mark	et cap	US\$ 2.1bn		
Free	float	31%		
3M ADV		US\$ 2.3mn		
52wk high/low		Rs 1,304/Rs 725		
Promoter/FPI/DII		70%/5%/13%		

Source: NSE | Price as of 6 May 2025

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E			
Total revenue (Rs mn)	66,721	75,202	83,511			
EBITDA (Rs mn)	10,082	12,186	15,184			
Adj. net profit (Rs mn)	5,697	7,299	9,554			
Adj. EPS (Rs)	29.0	37.1	48.6			
Consensus EPS (Rs)	36.7	44.6	44.6			
Adj. ROAE (%)	11.8	13.8	16.2			
Adj. P/E (x)	30.6	23.9	18.2			
EV/EBITDA (x)	17.8	14.9	12.1			
Adj. EPS growth (%)	(7.4)	27.9	30.9			
Source: Company, Bloomberg, BOBCAPS Research						

Stock performance



Source: NSE





EBITDA Margin to inch up to 18% by FY27E – ALPM reported 15.4% EBITDA margin in 4QFY25 and 15.1% in FY25, driven by change in product mix. However, EBITDA margin likely to increase to 18% byFY27E, driven by 1) moderate hiring of ~100 MRs in FY26 resulting in higher productivity (Rs 4.3mn in FY25) in the domestic region, increasing in capacity utilisation rate (currently F2- Onco -25%, F3 - Injectables -30% and F4 OSD – 60%) 3) new product launches in the US region in FY26 4) higher growth in high-margin RoW market.

WC days lower in FY26 – In FY25, working capital (WC) days have stretched from 148 days in FY25 to 110 days in FY24. The elongated days were due to a higher cash conversion cycle, which was 154 days in FY25 vs 113 days in FY24; primarily due to higher inventory days that increased to 148 days in FY25 from 110 days in FY24. Inventory days were higher as the company was building inventory due to scheduled multiple launches that got deferred. Also, the company has started a new manufacturing plant in Jarod, for which it has stocked up inventories like API etc. However, inventory days are expected to normalize in FY26.

Higher FCF generation to result in debt repayment in FY26 – In FY25, borrowings rose by 200% to Rs 11.6bn, primarily due to increase in short-term debt required to fund working capital. However, due to better operations, we expect the company to generate FCF of ~6bn in FY26, which would aid in debt repayment in FY26E.

Outlook & Valuation – We expect FY26 to be better than FY25 on all counts where sales in domestic segment is expected to grow in double digits, supported by growth from larger therapies in the acute segment, sustenance of high growth momentum in RoW market, new-products-driven mid-teens growth in the US region, and a likely API segment growth in FY26. Healthy operating to result in better margins and FCF generation as the majority of capex (Rs 5.6 bn) required for opening a new facility in Indore is over.

We factor in higher growth across geographies, followed by operating leverage. Hence, our EPS increases by 8.9% and 7.3% by FY26E and FY27E to Rs 37.1 and Rs 48.6 per share. Hence, we maintain BUY. At CMP, the stock is trading at attractive PE valuation of 23.9x in FY26E and 18.2x in FY27E. However, due to industry-lower ROCE and margins, we lower our ascribe PE to 21x (28x earlier) to arrive at TP of Rs 1,032.



Concall Highlights

Segmental Outlook

India region likely to grow by 10% in FY26

US region to grow by 15%, driven by new product launches

ROW market to grow by 12-15%

API segment to grow by 10%

India Region

Growth – domestic region sales grew by 8%, driven by growth in key segments like Gynecology, Anti Diabetic, Ophthalmology and Dermatology. Acute segment therapies like anti-infectives and cold and cough also reported growth of 11% and 7% respectively.

Animal Health - It continues to grow by 19% in 4QFY25 and 21% in FY25, backed by a basket of strong brands and new launches.

Outlook - Expect this segment to grow by 15-20%.

Field force- There are 5,500 field force as on FY25; likely to hire 100 MRs annually.

New Launches – Launched 4 new products in 4QFY25 and 14 new launches in FY25.

US region

Growth - The US business also grew 20% for the quarter, driven by higher volume growth, new product launches and lower base in 4QFY24.

Cumulative ANDAs- Cumulatively, we have 220 ANDA approvals and 163 products on the shelf.

New product launches – Launched 4 products in 4QFY25 and expect to launch 4-5 products in 1QFY25. Expect 15 new launches in FY26, out of which 20-30% to be meaningful launches.

Tariff - No one has enough capacity in the US. All peers having plants in the US are supplying a mere fraction of volumes. So, most likely, it's going to be a macro issue that everyone will face. Also, jointly, assuming a pass-through, no one would have more than 5% to 10% of the total US volumes capacity.

R&D - R&D expense was 9% of sales at Rs 1.5 bn for the quarter and for the full year, it was Rs5.22 bn.

Outlook – Expect R&D cost to increase to Rs 6 – 6.5bn in FY26. Amongst that, 40% would be towards peptides, complex injectables and Ophthalmic while the rest is towards APIs and OSDs. Amongst filings, 45% would be towards injectables while the rest would be OSD, derma and Ophthalmic.



Working Capital – FY25 witnessed higher WC days of 148, primarily due to higher inventory and receivable days.

Inventory days – Inventory days increased to 125 in FY25 from 96 days in FY25, as the company had built up inventory for new product launch that got deferred. Management has also kept a backup of API and related products, followed by higher utilisation rate for manufacturing units leading to higher inventories.

Receivable days – Receivable days have been around 70-80 days for long. This has gone up slightly on account of last quarter sales and some new launches where collection days are a little higher for the new launches. That will also go back to about 75 days or so in the next few quarters.

Capex – Budgeted capex is about Rs 4 - 4.5 bn, due to some spillover of expense that would come from the existing products, projects like Indore and others included.

Gross margin – GM has fallen from a high of 74% to about 70% plus. Expect GM to sustain ~ 70% due to price erosion in the US and higher volume sales.

EBITDA margin – Focus on cost optimisation initiatives, improving facility utilisation, followed by R&D cost rationalisation can lift EBITDA margin to 18-19% eventually.

GLP opportunity – Semaglutide - Do not have day1 opportunity for Semaglutide in the US market; however, will be present in ROW markets.

Tirzepatide – Expect to be in the 1st wave of launch in the US and all markets.



Financial Highlights

Fig 1 – Financial Highlights

(Rs Mn)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	FY24	FY25	FY26E	FY27E
Net Sales	17,696	15,170	16.7	16,927	4.5	62,290	66,721	75,202	83,511
Total Expenses	14,977	12,569	19.2	14,325	4.6	52,953	56,639	63,016	68,326
(%) of net sales	85	83		85		85	85	84	82
Raw material consumed	5,306	3,794	39.9	4,395	20.7	17,151	17,934	19,928	21,713
(%) of net sales	30	25		26		28	27	27	26
Staff cost	3,936	4,019	(2.1)	3,975	(1.0)	14,463	15,623	17,498	19,248
(%) of net sales	22	26		23		23	23	23	23
R&D cost	1,416	588	141.0	1,354	4.5	4,800	5,200	6,200	6,500
(%) of net sales	8	4		8		8	8	8	8
SG&A	4,319	4,169	3.6	4,600	(6.1)	16,539	17,882	19,389	20,866
(%) of net sales	24	27		27		27	27	26	25
EBITDA	2,719	2,601	4.6	2,602	4.5	9,337	10,082	12,186	15,184
Depreciation	690	695	(0.7)	700	(1.5)	2,727	2,786	2,987	3,270
EBIT	2,029	1,906	6.5	1,902	6.7	6,611	7,297	9,199	11,915
Interest	245	109		223		562	788	748	634
Other Income	142	36		95		283	426	450	450
PBT	1,926	1,832	5.1	1,774	8.6	6,332	6,934	8,901	11,731
Less: Taxation	353	47		401		160	1,252	1,602	2,112
Less: Minority Interest	4	4		(11)		10	(9)	0	0
Recurring PAT	1,569	1,782	(12.0)	1,384	13.4	6,162	5,691	7,299	9,619
Exceptional items	0	0		0		0	129		0
Reported PAT	1,569	1,782	(12.0)	1,384	13.4	6,162	5,820	7,299	9,619
Key Ratios (%)									
Gross Margin	70.0	75.0	(498)	74.0	(402)	72.5	73.1	73.5	74.0
EBITDA Margin	15.4	17.1	(178)	15.4	(1)	15.0	15.1	16.2	18.2
Tax / PBT	18.3	2.5		22.6		2.5	18.1	18.0	18.0
NPM	8.9	11.7		8.2	69	9.9	8.5	9.7	11.5
EPS	8.0	9.1	(12.0)	7.1	12.8	31.4	29.0	37.1	48.9

Source: Company, BOBCAPS Research

Fig 2 – Revenue breakup

(Rs Mn)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	FY24	FY25	FY26E	FY27E
Formulations	14,280	11,880	20.2	14,340	(0.4)	49,825	55,390	62,739	69,801
India	5,450	5,030	8.3	6,140	(11.2)	22,000	23,390	25,925	28,447
US	5,080	4,230	20.1	5,210	(2.5)	17,300	19,570	22,394	24,773
ROW	3,750	2,620	43.1	2,990	25.4	10,525	12,430	14,419	16,582
API	3,420	3,300	3.6	2,590	32.0	12,465	11,330	12,463	13,709
Net Sales	17,700	15,180	16.6	16,931	4.5	62,290	66,720	75,202	83,511

Source: Company, BOBCAPS Research



Valuation methodology

ALPM reported above estimates earnings on all fronts, driven by growth across geographies. However, the change in product mix resulted in lower EBITDA margin of ~!5%. On the balance sheet front, short-term borrowings were elevated due to an increase in working capital days.

We expect FY26 to be better than FY25 on all counts where sales in the domestic segment are expected to grow in double digits, supported by growth from larger therapies in the acute segment, sustenance of high growth momentum in the RoW market, new-products-driven mid-teens growth in the US region and API segment expected to grow in FY26. Healthy operating to result in better margins and FCF generation as most of the capex (Rs 5.6 bn) required for opening a new facility in Indore is over.

We factor in higher growth across geographies, followed by operating leverage. Hence, our EPS increases by 8.9% and 7.3% by FY26E and FY27E to Rs 37.1 and Rs 48.6 per share. Hence, we maintain BUY. At CMP, the stock is trading at attractive PE valuation of 23.9x in FY26E and 18.2x in FY27E. However, due to industry-lower ROCE and margins, we lower our ascribe PE to 21x (28x earlier) to arrive at TP of Rs 1,032.

Fig 3 – Key	Assumption
-------------	------------

Key Assumptions	FY25	FY26E	FY27E
Revenue	66,721	75,202	83,511
EBITDA	10,082	12,186	15,184
PAT	5,697	7,299	9,554
EPS	29.7	37.1	48.6
EBITDA Margin	15.1	16.2	18.2
PAT Margin	8.5	9.7	11.4

Source: Company, BOBCAPS Research

Fig 4 – Change in Estimates

(Do mo)	New		Old		Change	e (%)
(Rs mn)	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Sales	75,202	83,511	72,954	80,336	3.1	4.0
EBITDA	12,186	15,184	11,825	14,780	3.0	2.7
EBITDA margin (%)	16.2	18.2	16.2	18.4	(0bps)	(22bps)
EPS (Rs)	37.1	48.6	34.1	45.3	8.9	7.3

Source: Company, BOBCAPS Research

Key risks

Key downside risks to our estimates:

- Adverse action on manufacturing facilities catering to the US
- Slow pace of new approvals/launches



Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25A	FY26E	FY27E
Total revenue	56,526	62,290	66,721	75,202	83,511
EBITDA	7,083	9,337	10,082	12,186	15,184
Depreciation	2,754	2,727	2,786	2,987	3,270
EBIT	4,329	6,611	7,297	9,199	11,915
Net interest inc./(exp.)	(502)	(562)	(788)	(748)	(713)
Other inc./(exp.)	27	283	426	450	450
Exceptional items	0	0	0	0	0
EBT	3,855	6,332	6,934	8,901	11,652
Income taxes	126	160	1,252	1,602	2,097
Extraordinary items	0	0	129	0	0
Min. int./Inc. from assoc.	0	0	(14)	0	0
Reported net profit	3,729	6,172	5,825	7,299	9,554
Adjustments	0	0	129	0	0
Adjusted net profit	3,729	6,172	5,697	7,299	9,554

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25A	FY26E	FY27E
Accounts payables	6,798	7,356	8,799	9,683	10,525
Other current liabilities	2,343	2,038	2,358	2,256	835
Provisions	1,763	1,748	2,102	2,369	2,631
Debt funds	7,220	5,132	12,575	8,803	7,042
Other liabilities	0	0	0	0	0
Equity capital	393	393	393	393	393
Reserves & surplus	42,082	46,093	49,842	54,978	62,371
Shareholders' fund	42,475	46,486	50,235	55,371	62,764
Total liab. and equities	60,598	62,759	76,069	78,482	83,796
Cash and cash eq.	823	1,266	901	1,089	1,414
Accounts receivables	10,464	10,248	13,998	15,452	17,160
Inventories	14,753	16,435	22,881	22,663	22,880
Other current assets	3,598	3,169	3,409	3,008	5,011
Investments	963	930	1,272	1,272	1,272
Net fixed assets	23,985	25,467	25,235	26,625	27,687
CWIP	6,013	5,244	8,372	8,372	8,372
Intangible assets	0	0	0	0	0
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	60,598	62,759	76,069	78,482	83,796

Cash Flows

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25A	FY26E	FY27E
Cash flow from operations	5,352	8,651	1,089	11,247	9,293
Capital expenditures	(8,665)	(3,450)	(5,636)	(4,376)	(4,332)
Change in investments	221	33	(342)	0	0
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(8,445)	(3,417)	(5,978)	(4,376)	(4,332)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	49	(2,089)	7,443	(3,773)	(1,761)
Interest expenses	(502)	(562)	(788)	(748)	(713)
Dividends paid	(1,966)	(2,162)	(2,162)	(2,162)	(2,162)
Other financing cash flows	5,639	21	31	0	0
Cash flow from financing	3,221	(4,792)	4,524	(6,683)	(4,636)
Chg in cash & cash eq.	128	443	(365)	189	325
Closing cash & cash eq.	823	1,266	901	1,089	1,414

Y/E 31 Mar (Rs)	FY23A	FY24A	FY25A	FY26E	FY27E
Reported EPS	17.4	31.4	29.7	37.1	48.6
Adjusted EPS	17.4	31.4	29.0	37.1	48.6
Dividend per share	10.0	11.0	11.0	11.0	11.0
Book value per share	216.1	236.5	255.6	281.7	319.3
Valuations Ratios					
Y/E 31 Mar (x)	FY23A	FY24A	FY25A	FY26E	FY27E
EV/Sales	3.2	2.9	2.7	2.4	2.2
EV/EBITDA	25.4	19.4	17.8	14.9	12.1
Adjusted P/E	51.0	28.3	30.6	23.9	18.2
P/BV	4.1	3.7	3.5	3.1	2.8
DuPont Analysis					
Y/E 31 Mar (%)	FY23A	FY24A	FY25A	FY26E	FY27E
Tax burden (Net profit/PBT)	96.7	97.5	82.2	82.0	82.0
Interest burden (PBT/EBIT)	89.0	95.8	95.0	96.8	97.8
EBIT margin (EBIT/Revenue)	7.7	10.6	10.9	12.2	14.3
Asset turnover (Rev./Avg TA)	25.9	30.7	29.2	29.6	31.2
Leverage (Avg TA/Avg Equity)	1.2	1.1	1.2	1.2	1.1
Adjusted ROAE	7.2	13.9	11.8	13.8	16.2
Ratio Analysis					
Y/E 31 Mar	FY23A	FY24A	FY25A	FY26E	FY27E
YoY growth (%)					
Revenue	6.5	10.2	7.1	12.7	11.0
EBITDA	(19.0)	31.8	8.0	20.9	24.6
Adjusted EPS	(34.4)	80.2	(7.4)	27.9	30.9
Profitability & Return ratios (%)				
EBITDA margin	12.5	15.0	15.1	16.2	18.2
EBIT margin	7.7	10.6	10.9	12.2	14.3
Adjusted profit margin	6.6	9.9	8.5	9.7	11.4
Adjusted ROAE	7.2	13.9	11.8	13.8	16.2
ROCE	8.0	13.6	13.5	15.2	18.5
Working capital days (days)					
Receivables	68	60	77	75	75
Inventory	95	96	125	110	100
Payables	44	43	48	47	46
Ratios (x)					

1.6

2.8

11.8

1.5

3.1

9.3

0.2

1.6

3.0

12.3

0.1

1.6

3.3 16.7

0.1

1.6

2.7

8.6

 Adjusted debt/equity
 0.2
 0.1

 Source: Company, BOBCAPS Research | Note: TA = Total Assets

Gross asset turnover

Net interest coverage ratio

Current ratio

ALEMBIC PHARMA



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

 $BUY-\mbox{Expected return}>+15\%$


HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): ALEMBIC PHARMA (ALPM IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of Individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

ALEMBIC PHARMA



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or merchan banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.